PHARMAGENIC ENRICHMENT
Live / Registered — Registered (as of 29 Apr 2025)
What this means for you
Registered since 29 Apr 2025. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 79389202
- Registration number
- 7772657
- Mark type
- Stylized text
- Filed
- 17 Jan 2024
- Published for opposition
- 11 Mar 2025
- Registered
- 29 Apr 2025
- Attorney of record
- Fatima Kassem
Goods and services
- Class 044 — Medical, beauty and agricultural services: Advisory services relating to pharmaceutical products, namely, providing information to patients in the field of administering medication; provision of pharmaceutical medical information; genetic testing for medical purposes; medical advisory services relating to medical problems; medical advisory services relating to medical services; alternative medical services; arranging of medical treatment, namely, providing medical treatment of chronic diseases in the nature of cardiometabolic, inflammatory, neurological, psychiatric, ophthalmological, musculoskeletal, respiratory, oncological, fibrotic, dermatological, hepatic and renal diseases; cardiology medical services; complementary medical services; conducting of medical examinations; general practice (GP) medical services; fitness testing, namely, medical testing for fitness evaluation; gastroenterology medical services; endocrinology medical services; dietetic counselling services, namely, dietic advisory services; medical consultancy and advisory services in relation to medical services; medical analysis of tissues for medical treatment for persons; health care consultancy services; health farm services in the nature of health spa services for health and wellness of the body and spirit offered at a health club facility; medical advice for individuals with disabilities; medical advisory services; medical analysis services relating to the treatment of patients; medical analysis services for diagnostic and treatment purposes provided by medical laboratories; medical analysis services for the diagnosis and treatment of persons; medical assistance; medical care services; medical clinic services; medical consulting services relating to offshore medical services; medical counselling; medical diagnostic services; medical examination of individuals; medical health assessment services; medical services in the field of oncology; medical screening; medical services; medical treatment services, namely, medical treatment of cardiometabolic, inflammatory, neurological, psychiatric, ophthalmological, musculoskeletal, respiratory, oncological, fibrotic, dermatological, hepatic and renal diseases; medical treatment using cultured cells; neurology medical services; oncology medical services; ophthalmology medical services; pediatric medical services; preparation of reports relating to medical matters in the nature of providing medical information to patients, medical professionals, medical providers, pharmacists, pathologists, pathology service providers, medical payers, including public and private health insurers, medical device distributors, pharmaceutical distributors, and biotechnology companies in the form of reports in the field of complex traits and disorders relating to cardiometabolic, inflammatory, neurological, psychiatric, ophthalmological, musculoskeletal, respiratory, oncological, fibrotic, dermatological, hepatic and renal diseases, including pharmaceutical-gene interactions, and predictions of the magnitude of response to treatments and interventions; providing medical information including online, about medical services; provision of medical assistance; provision of medical facilities, namely, leasing of equipped medical facilities that medical professionals can use on an as-needed basis; provision of medical information; provision of medical services; provision of medical treatment of cardiometabolic, inflammatory, neurological, psychiatric, ophthalmological, musculoskeletal, respiratory, oncological, fibrotic, dermatological, hepatic and renal diseases; services for the preparation of medical reports in the nature of providing medical information to patients, medical professionals, medical providers, pharmacists, pathologists, pathology service providers, medical payers, including public and private health insurers, medical device distributors, pharmaceutical distributors, and biotechnology companies in the form of reports in the field of cardiometabolic, inflammatory, neurological, psychiatric, ophthalmological, musculoskeletal, respiratory, oncological, fibrotic, dermatological, hepatic and renal diseases
Owner
- PolygenRx Pty Ltd, AU
- PolygenRx Pty Ltd, AU
- PolygenRx Pty Ltd, AU
Prosecution history
- 05 Dec 2025 — FINAL DECISION TRANSACTION PROCESSED BY IB
- 19 Nov 2025 — FINAL DISPOSITION NOTICE SENT TO IB
- 19 Nov 2025 — FINAL DISPOSITION PROCESSED
- 29 Jul 2025 — FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
- 26 Jul 2025 — NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
- 07 Jul 2025 — NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
- 07 Jul 2025 — NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
- 29 Apr 2025 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 29 Apr 2025 — REGISTERED-PRINCIPAL REGISTER
- 11 Mar 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 11 Mar 2025 — PUBLISHED FOR OPPOSITION
- 05 Mar 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 15 Feb 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 04 Feb 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 04 Feb 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE